"Anti-Arrhythmia Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
| Descriptor ID |
D000889
|
| MeSH Number(s) |
D27.505.954.411.097
|
| Concept/Terms |
Anti-Arrhythmia Agents- Anti-Arrhythmia Agents
- Agents, Anti-Arrhythmia
- Anti Arrhythmia Agents
- Antiarrhythmic Drugs
- Drugs, Antiarrhythmic
- Antiarrhythmia Agents
- Agents, Antiarrhythmia
- Antiarrhythmia Drugs
- Drugs, Antiarrhythmia
- Anti-Arrhythmia Drugs
- Anti Arrhythmia Drugs
- Drugs, Anti-Arrhythmia
- Anti-Arrhythmics
- Anti Arrhythmics
Cardiac Depressants- Cardiac Depressants
- Depressants, Cardiac
- Myocardial Depressants
- Depressants, Myocardial
|
Below are MeSH descriptors whose meaning is more general than "Anti-Arrhythmia Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Arrhythmia Agents".
This graph shows the total number of publications written about "Anti-Arrhythmia Agents" by people in this website by year, and whether "Anti-Arrhythmia Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Arrhythmia Agents" by people in Profiles.
-
Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. Am J Cardiol. 2020 02 15; 125(4):553-561.
-
Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart. 2018 11; 104(22):1850-1858.
-
Ibutilide Effectiveness and Safety in the Cardioversion of Atrial Fibrillation and Flutter in the Community Emergency Department. Ann Emerg Med. 2018 Jan; 71(1):96-108.e2.
-
Emergency Department Management of Atrial Fibrillation and Flutter and Patient Quality of Life at One Month Postvisit. Ann Emerg Med. 2015 Dec; 66(6):646-654.e2.
-
Use of statins and antihypertensive medications in relation to risk of long-standing persistent atrial fibrillation. Ann Pharmacother. 2015 Apr; 49(4):378-86.
-
Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015 Feb; 8(1):49-58.
-
Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm. 2012 Sep; 9(9):1403-8.
-
Partner quality of life in the antiarrhythmics versus implantable defibrillators trial. J Cardiovasc Nurs. 2007 Nov-Dec; 22(6):472-9.
-
What do medical records tell us about potentially harmful co-prescribing? Jt Comm J Qual Patient Saf. 2007 Jul; 33(7):395-400.
-
Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf. 2006 Jun; 15(6):361-8.